查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298392

抗酸劑市場：按作用方式、製劑類型、分銷渠道：2023-2032 年全球機會分析和行業預測

Antacids Market By Mechanism of Action, By Formulation Type, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 249 Pages | 商品交期: 2-3個工作天內

價格

2022年抗酸劑市場價值為66.7882億美元，預計到2032年將達到90.6847億美元，2023年至2032年的複合年增長率為3.1%。

Antacids Market-IMG1

抗酸劑是用於緩解胃灼熱和消化不良的藥物。這些藥物通過減少胃分泌的鹽酸量起作用。胃分泌鹽酸進行消化。由於酸具有腐蝕性，粘膜屏障可以保護胃壁免受侵蝕。然而，與胃酸反流和粘膜屏障相關的問題可能會導致胃灼熱。在這種情況下，抗酸劑用於中和胃中存在的酸，產生中性物質，例如水和鹽。這可以減少胃酸並緩解胃灼熱和消化不良的症狀。

抗酸劑有許多不同類型，包括片劑和液體，它們的味道和強度各不相同。這些藥物在中等劑量下是安全的，並且對輕微症狀有效。抗酸劑中常見的成分包括氫氧化鋁、氫氧化鎂、碳酸鈣和碳酸氫鈉。一些抗酸劑也用於緩解脹氣和腹脹，例如西甲矽油與碳酸鈣的組合以及氫氧化鎂與西甲矽油的組合。

全球抗酸劑市場的增長是由酸相關疾病的日益流行、非處方（OTC）抗酸劑的便利性和可用性以及自我用藥患者數量的增加推動的。胃酸相關疾病包括胃酸分泌過多引起的各種胃腸道疾病，例如胃食管反流病(GERD)、消化性潰瘍和消化不良。這些與酸相關的疾病的日益流行是抗酸劑市場的主要驅動力。例如，根據國家醫學圖書館 2020 年的數據，超過 6000 萬美國人每月至少經歷一次胃灼熱。

然而，過度使用抗酸劑會導致各種副作用並阻礙市場增長。例如，抗酸劑會影響體內鈉、鉀和鈣等電解質水平。長期使用抗酸劑還會加重腎臟負擔，導致腎結石和腎衰竭等問題。此外，欠發達國家人群對胃酸反流和胃食管反流病（GERD）等疾病和治療的認識較低也是市場的主要製約因素。

另一方面，越來越多的製造商專注於開發各種具有成本效益且副作用很少的藥物，預計將為市場增長提供利潤豐厚的機會。例如，Alkem Laboratories 提供各種口味的 Omee MPS Liquids，如薄荷、橙子和 Saunfu，以及相同口味的 Omee Chua Tabs。這些抗酸劑的價格實惠，使其在發展中國家和發達國家得到越來越多的採用。

目錄

第 1 章 簡介

第二章執行摘要

第三章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資口袋
  • 波特五力分析
    • 供應商的議價能力
    • 買方議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 促進者
      • 胃酸反流和胃食管反流病患病率增加
      • 輕鬆獲得非處方抗酸劑
      • 老齡化人口對抗酸劑的需求猛增
    • 阻礙因素
      • 限制使用抗酸劑
      • 替代療法的出現
    • 機會
      • 世界人口生活方式的快速變化
  • COVID-19 市場影響分析

4 抗酸劑市場（按作用機制）

  • 概述
    • 市場規模及預測
  • 全身抗酸劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 非全身性抗酸劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

5. 抗酸劑市場，按製劑類型

  • 概述
    • 市場規模和預測
  • 藥片
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 液體
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

6. 抗酸劑市場（按分銷渠道）

  • 概述
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 藥店和零售藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 在線提供商
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

7.按地區劃分的抗酸劑市場

  • 概述
    • 市場規模/預測：按地區
  • 北美
    • 主要趨勢和機遇
    • 市場規模和預測：按作用機制
    • 市場規模/預測：按配方類型
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
  • 歐洲
    • 主要趨勢和機遇
    • 市場規模和預測：按作用機制
    • 市場規模/預測：按配方類型
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 歐洲其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
  • 亞太地區
    • 主要趨勢和機遇
    • 市場規模和預測：按作用機制
    • 市場規模/預測：按配方類型
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 亞太其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 市場規模和預測：按作用機制
    • 市場規模/預測：按配方類型
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分
      • 其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按作用機制
      • 市場規模/預測：按配方類型
      • 市場規模和預測：按分銷渠道劃分

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10大公司產品圖
  • 比賽儀表板
  • 比賽熱圖
  • 2022 年頂級公司定位

第九章公司簡介

  • Bayer AG
  • Alkem Laboratories Ltd.
  • Cipla Ltd
  • Pfizer Inc.
  • WellSpring Pharmaceutical Corporation
  • Haleon plc
  • Prestige Consumer Healthcare Inc.
  • Reckitt Benckiser Group PLC
  • Infirst Healthcare Inc.
  • Abbott Laboratories
Product Code: A10281

The antacids market valued for $6,678.82 million in 2022 and is estimated to reach $9,068.47 million by 2032, exhibiting a CAGR of 3.1% from 2023 to 2032.

Antacids Market - IMG1

Antacid is a medication that is used to alleviate heartburn and indigestion. These medications act by reducing the amount of hydrochloric acid secreted in the stomach. The stomach secretes hydrochloric acid to carry out the digestion process. As the acid is corrosive, a mucous barrier protects the lining of the stomach from being eroded. However, acid reflux or issues associated with the mucous barrier can result in heartburn. This In such cases, antacids are used to neutralize the acid present in the stomach to produce a neutral substance, such as water or salt. This reduces the acidity in the stomach and relieves symptoms of heartburn and indigestion.

Antacids are available in various types of formulations such as tablets, liquids, and others, along with a range of flavors and strengths. These medications are safe to use in moderation and can be effective for mild symptoms. Common ingredients in antacids include aluminum hydroxide, magnesium hydroxide, calcium carbonate, and sodium bicarbonate. Some antacids are given in combination such as simethicone along with calcium carbonate or magnesium hydroxide and simethicone, which is used to relieve gas and bloating.

The growth of the global antacids market is driven increase in prevalence of acid-related conditions, convenience & accessibility of over-the-counter (OTC) antacids, and rise in number of patients engaging in self-medication. Acid-related conditions involve a range of gastrointestinal disorders that are caused by excessive secretion of gastric acid, such as gastroesophageal reflux disease (GERD), peptic ulcers, and dyspepsia. Increase in prevalence of these acid-related conditions acts as a major driver of the antacids market. For instance, according to the National Library of Medicine in 2020, more than 60 million Americans experience heartburn at least once a month.

However, excessive use of antacids leads to a range of side effects that potentially hinder the growth of the market. For instance, antacids may affect the levels of electrolytes in the body, such as sodium, potassium, and calcium. In addition, prolonged use of antacids can put strain on the kidneys, leading to problems such as kidney stones or renal failure. In addition, low awareness about acid reflux, gastroesophageal reflux disease (GERD), and other conditions and available treatment among the population of underdeveloped countries acts as a key restraint of the market.

On the contrary, increase in focus of manufacturers to develop cost-effective and wide range of medications with less side effects is expected to offer lucrative opportunities for the market growth. For instance, Alkem Laboratories offers Omee MPS liquid, which is available in a range of flavors such as mint, orange, and saunf as well as Omee Chewtabs, which are available in the same flavors. These antacids are affordable, and thus, have witnessed increased adoption in developing and developed countries.

In addition, people in underdeveloped countries are becoming aware about antacid medications available in the market and their use in managing acidity and other acid-related conditions. This is anticipated to boost the market during the forecast period. In addition, emerging countries in Asia-Pacific and LAMEA are characterized by presence of large population base along with rapid economic growth and increase in healthcare expenditure. All these factors are anticipated to increase the demand for antacids in these regions, thereby boosting the global market growth.

The global antacids market is segmented into medication type, formulation type, distribution channel, and region. By product, the market is bifurcated into systemic antacids and non-systemic antacids. On the basis of formulation type, it is categorized into tablet, liquids, and others. By distribution channel, it is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the Abbott Laboratories, Pfizer Inc., Prestige Consumer Healthcare Inc., Cipla Ltd, Reckitt Benckiser Group PLC, Haleon plc, Bayer AG, Alkem Laboratories Ltd., WellSpring Pharmaceutical Corporation and Infirst Healthcare Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antacids market analysis from 2022 to 2032 to identify the prevailing antacids market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the antacids market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global antacids market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Mechanism of Action

  • Systemic Antacids
  • Non-systemic Antacids

By Formulation Type

  • Tablets
  • Liquids
  • Others

By Distribution channel

  • Hospital pharmacies
  • Drug stores and retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Abbott Laboratories
    • Alkem Laboratories Ltd.
    • Bayer AG
    • Cipla Ltd
    • Haleon plc
    • Infirst Healthcare Inc.
    • Pfizer Inc.
    • Prestige Consumer Healthcare Inc.
    • Reckitt Benckiser Group PLC
    • WellSpring Pharmaceutical Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of acid reflux and GERD
      • 3.4.1.2. Easy availability of OTC antacids
      • 3.4.1.3. Surge in demand for antacids among geriatric population
    • 3.4.2. Restraints
      • 3.4.2.1. Limitations related to use of antacids
      • 3.4.2.2. Emergence of alternative treatments
    • 3.4.3. Opportunities
      • 3.4.3.1. Rapidly changing lifestyle of global population
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: ANTACIDS MARKET, BY MECHANISM OF ACTION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Systemic Antacids
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Non-systemic Antacids
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: ANTACIDS MARKET, BY FORMULATION TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Tablets
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Liquids
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: ANTACIDS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug stores and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: ANTACIDS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Mechanism of Action
    • 7.2.3. Market size and forecast, by Formulation Type
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Mechanism of Action
      • 7.2.5.1.3. Market size and forecast, by Formulation Type
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Mechanism of Action
      • 7.2.5.2.3. Market size and forecast, by Formulation Type
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Mechanism of Action
      • 7.2.5.3.3. Market size and forecast, by Formulation Type
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Mechanism of Action
    • 7.3.3. Market size and forecast, by Formulation Type
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Mechanism of Action
      • 7.3.5.1.3. Market size and forecast, by Formulation Type
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Mechanism of Action
      • 7.3.5.2.3. Market size and forecast, by Formulation Type
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Mechanism of Action
      • 7.3.5.3.3. Market size and forecast, by Formulation Type
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Mechanism of Action
      • 7.3.5.4.3. Market size and forecast, by Formulation Type
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Mechanism of Action
      • 7.3.5.5.3. Market size and forecast, by Formulation Type
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Mechanism of Action
      • 7.3.5.6.3. Market size and forecast, by Formulation Type
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Mechanism of Action
    • 7.4.3. Market size and forecast, by Formulation Type
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Mechanism of Action
      • 7.4.5.1.3. Market size and forecast, by Formulation Type
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Mechanism of Action
      • 7.4.5.2.3. Market size and forecast, by Formulation Type
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Mechanism of Action
      • 7.4.5.3.3. Market size and forecast, by Formulation Type
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Mechanism of Action
      • 7.4.5.4.3. Market size and forecast, by Formulation Type
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Mechanism of Action
      • 7.4.5.5.3. Market size and forecast, by Formulation Type
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Mechanism of Action
      • 7.4.5.6.3. Market size and forecast, by Formulation Type
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Mechanism of Action
    • 7.5.3. Market size and forecast, by Formulation Type
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Mechanism of Action
      • 7.5.5.1.3. Market size and forecast, by Formulation Type
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Mechanism of Action
      • 7.5.5.2.3. Market size and forecast, by Formulation Type
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Mechanism of Action
      • 7.5.5.3.3. Market size and forecast, by Formulation Type
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Mechanism of Action
      • 7.5.5.4.3. Market size and forecast, by Formulation Type
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Bayer AG
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Alkem Laboratories Ltd.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Cipla Ltd
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Pfizer Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. WellSpring Pharmaceutical Corporation
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
  • 9.6. Haleon plc
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Prestige Consumer Healthcare Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Reckitt Benckiser Group PLC
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Infirst Healthcare Inc.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
  • 9.10. Abbott Laboratories
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 02. ANTACIDS MARKET FOR SYSTEMIC ANTACIDS , BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. ANTACIDS MARKET FOR NON-SYSTEMIC ANTACIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GLOBAL ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 05. ANTACIDS MARKET FOR TABLETS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. ANTACIDS MARKET FOR LIQUIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. ANTACIDS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 09. ANTACIDS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. ANTACIDS MARKET FOR DRUG STORES AND RETAIL PHARMACIES , BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. ANTACIDS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. ANTACIDS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA ANTACIDS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 18. U.S. ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. CANADA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 21. CANADA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE ANTACIDS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. UK ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 37. UK ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. ITALY ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 40. ITALY ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. REST OF EUROPE ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. ASIA-PACIFIC ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC ANTACIDS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. JAPAN ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. CHINA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 56. CHINA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. INDIA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 59. INDIA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 60. INDIA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. LAMEA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA ANTACIDS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 74. BRAZIL ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. SAUDI ARABIA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 78. SAUDI ARABIA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 80. SOUTH AFRICA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 81. SOUTH AFRICA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. REST OF LAMEA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LAMEA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. BAYER AG: KEY EXECUTIVES
  • TABLE 87. BAYER AG: COMPANY SNAPSHOT
  • TABLE 88. BAYER AG: PRODUCT SEGMENTS
  • TABLE 89. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 90. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 91. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 92. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 93. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 94. CIPLA LTD: KEY EXECUTIVES
  • TABLE 95. CIPLA LTD: COMPANY SNAPSHOT
  • TABLE 96. CIPLA LTD: PRODUCT SEGMENTS
  • TABLE 97. CIPLA LTD: PRODUCT PORTFOLIO
  • TABLE 98. PFIZER INC.: KEY EXECUTIVES
  • TABLE 99. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 100. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 101. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 102. WELLSPRING PHARMACEUTICAL CORPORATION: KEY EXECUTIVES
  • TABLE 103. WELLSPRING PHARMACEUTICAL CORPORATION: COMPANY SNAPSHOT
  • TABLE 104. WELLSPRING PHARMACEUTICAL CORPORATION: PRODUCT SEGMENTS
  • TABLE 105. WELLSPRING PHARMACEUTICAL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 106. HALEON PLC: KEY EXECUTIVES
  • TABLE 107. HALEON PLC: COMPANY SNAPSHOT
  • TABLE 108. HALEON PLC: PRODUCT SEGMENTS
  • TABLE 109. HALEON PLC: PRODUCT PORTFOLIO
  • TABLE 110. PRESTIGE CONSUMER HEALTHCARE INC.: KEY EXECUTIVES
  • TABLE 111. PRESTIGE CONSUMER HEALTHCARE INC.: COMPANY SNAPSHOT
  • TABLE 112. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT SEGMENTS
  • TABLE 113. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT PORTFOLIO
  • TABLE 114. RECKITT BENCKISER GROUP PLC: KEY EXECUTIVES
  • TABLE 115. RECKITT BENCKISER GROUP PLC: COMPANY SNAPSHOT
  • TABLE 116. RECKITT BENCKISER GROUP PLC: PRODUCT SEGMENTS
  • TABLE 117. RECKITT BENCKISER GROUP PLC: PRODUCT PORTFOLIO
  • TABLE 118. INFIRST HEALTHCARE INC.: KEY EXECUTIVES
  • TABLE 119. INFIRST HEALTHCARE INC.: COMPANY SNAPSHOT
  • TABLE 120. INFIRST HEALTHCARE INC.: PRODUCT SEGMENTS
  • TABLE 121. INFIRST HEALTHCARE INC.: PRODUCT PORTFOLIO
  • TABLE 122. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 123. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 124. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 125. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. ANTACIDS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF ANTACIDS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN ANTACIDS MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALANTACIDS MARKET
  • FIGURE 10. ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR SYSTEMIC ANTACIDS , BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR NON-SYSTEMIC ANTACIDS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. ANTACIDS MARKET, BY FORMULATION TYPE, 2022(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR TABLETS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR LIQUIDS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR DRUG STORES AND RETAIL PHARMACIES , BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. ANTACIDS MARKET BY REGION, 2022
  • FIGURE 22. U.S. ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. CANADA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. MEXICO ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. GERMANY ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. FRANCE ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. UK ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. ITALY ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. SPAIN ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. REST OF EUROPE ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. JAPAN ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CHINA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. INDIA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. AUSTRALIA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. SOUTH KOREA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. BRAZIL ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SAUDI ARABIA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SOUTH AFRICA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. REST OF LAMEA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45. COMPETITIVE DASHBOARD
  • FIGURE 46. COMPETITIVE HEATMAP: ANTACIDS MARKET
  • FIGURE 47. TOP PLAYER POSITIONING, 2022
  • FIGURE 48. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 50. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 51. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. HALEON PLC: NET SALES, 2021-2021 ($MILLION)
  • FIGURE 60. PRESTIGE CONSUMER HEALTHCARE INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 62. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 63. RECKITT BENCKISER GROUP PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. RECKITT BENCKISER GROUP PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. RECKITT BENCKISER GROUP PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 67. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)